Intellectual Capital and Anticipated Future Sales in Small and Medium-sized Biotechnology Companies
AbstractNo abstract is available for this item.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by The Research Institute of the Finnish Economy in its series Discussion Papers with number 856.
Length: 30 pages
Date of creation: 2003
Date of revision:
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Ismo Linnosmaa & Raine Hermans & Taru Hallinen, 2004. "Price-cost margin in the pharmaceutical industry," The European Journal of Health Economics, Springer, vol. 5(2), pages 122-128, May.
- Michael R. Darby & Lynne G. Zucker, 2002. "Going Public When You Can in Biotechnology," NBER Working Papers 8954, National Bureau of Economic Research, Inc.
- Robert E. Hall, 2000.
"The stock market and capital accumulation,"
Federal Reserve Bank of San Francisco, issue Apr.
- Tahvanainen, Antti-Jussi & Hermans, Raine, 2004. "Financial Pecking Order and the Value Platform of Intellectual Capital," Discussion Papers 926, The Research Institute of the Finnish Economy.
- Tahvanainen, Antti-Jussi, 2004. "Academic Spin-offs in Finnish Biotechnology," Discussion Papers 900, The Research Institute of the Finnish Economy.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Kaija Hyvönen-Rajecki).
If references are entirely missing, you can add them using this form.